MX9300948A - A NOVEL ANTAGONIST OF THE 5HT3 RECEIVER - Google Patents

A NOVEL ANTAGONIST OF THE 5HT3 RECEIVER

Info

Publication number
MX9300948A
MX9300948A MX9300948A MX9300948A MX9300948A MX 9300948 A MX9300948 A MX 9300948A MX 9300948 A MX9300948 A MX 9300948A MX 9300948 A MX9300948 A MX 9300948A MX 9300948 A MX9300948 A MX 9300948A
Authority
MX
Mexico
Prior art keywords
treatment
receiver
antagonist
novel
novel antagonist
Prior art date
Application number
MX9300948A
Other languages
Spanish (es)
Inventor
Maurice W Gittos
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of MX9300948A publication Critical patent/MX9300948A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se relaciona con el octahidro 3-hidroxi-2,6-metano-2H-qunolizin-8-il éster del ácido 5-cloro-2,3-dihidro-2,2-dimetilbenzofuran-7-carbox ílico, un antagonista novedoso del receptor 5-HT3, con su método de preparación y con su uso final en la aplicación en el tratamiento de las náuseas y el vómito, en el tratamiento del dolor asociado con migraña, en el tratamiento de psicosis endógena alucinatoria del tipo manifestado en pacientes que sufren de esquizofrenia y manía, para el síndrome del intestino inflamatorio o irritable o para combatir el abuso de las drogas.This invention relates to 5-chloro-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acid 3-hydroxy-2,6-methane-2H-qunolizin-8-yl ester, an antagonist Novel 5-HT3 receptor, with its preparation method and with its final use in the application in the treatment of nausea and vomiting, in the treatment of pain associated with migraine, in the treatment of hallucinatory endogenous psychosis of the type manifested in patients suffering from schizophrenia and mania, for inflammatory or irritable bowel syndrome or to combat drug abuse.

MX9300948A 1992-02-24 1993-02-22 A NOVEL ANTAGONIST OF THE 5HT3 RECEIVER MX9300948A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92400474 1992-02-24

Publications (1)

Publication Number Publication Date
MX9300948A true MX9300948A (en) 1993-08-01

Family

ID=8211614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300948A MX9300948A (en) 1992-02-24 1993-02-22 A NOVEL ANTAGONIST OF THE 5HT3 RECEIVER

Country Status (14)

Country Link
EP (1) EP0628043A1 (en)
JP (1) JPH07504192A (en)
KR (1) KR100287933B1 (en)
AU (1) AU675060B2 (en)
CA (1) CA2130563C (en)
FI (1) FI105917B (en)
HU (1) HU216831B (en)
IL (1) IL104821A (en)
MX (1) MX9300948A (en)
NO (1) NO943101L (en)
NZ (1) NZ249346A (en)
TW (1) TW226374B (en)
WO (1) WO1993017019A1 (en)
ZA (1) ZA931146B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2672500A (en) 1999-02-18 2000-09-04 Novartis Ag Systemic use of 5-ht3 receptor antagonists against rheumatic inflammatory processes
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (en) 2005-03-07 2019-05-27 Univ Chicago Use of opioid antagonists to attenuate the proliferation and migration of endothelial cells
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329932B1 (en) * 1988-02-23 1995-10-18 Merrell Pharmaceuticals Inc. Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments
EP0517984A1 (en) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Derivatives of amide analogs of certain methano bridged quinolizines

Also Published As

Publication number Publication date
HU216831B (en) 1999-09-28
EP0628043A1 (en) 1994-12-14
IL104821A0 (en) 1993-06-10
NZ249346A (en) 1995-10-26
HU9402436D0 (en) 1994-10-28
JPH07504192A (en) 1995-05-11
ZA931146B (en) 1993-09-14
KR950700297A (en) 1995-01-16
AU3603493A (en) 1993-09-13
TW226374B (en) 1994-07-11
FI943872A0 (en) 1994-08-23
FI943872A (en) 1994-08-23
CA2130563A1 (en) 1993-09-02
FI105917B (en) 2000-10-31
KR100287933B1 (en) 2001-05-02
HUT68249A (en) 1995-06-28
NO943101D0 (en) 1994-08-23
IL104821A (en) 1997-01-10
AU675060B2 (en) 1997-01-23
WO1993017019A1 (en) 1993-09-02
NO943101L (en) 1994-08-23
CA2130563C (en) 1997-11-11

Similar Documents

Publication Publication Date Title
EA199800340A1 (en) DERIVATIVES OF PYRIMIDINE AS ANTAGONISTS 5HT2S
UA27776C2 (en) Quinuclidine derivatives, pharmaceutically acceptable saults thereof which are substance p receptor antagonists in mammals, pharmaceutical composition possessing antagonist activity on substance p in mammals
EA199900045A1 (en) DERIVATIVES OF SPIROPIPERIDINE AND THEIR USE AS THERAPEUTIC AGENTS
BR9609013A (en) Nucleoside analog, and, compound.
MX9300977A (en) HETEROBICICLIC COMPOUNDS.
MY132229A (en) Indole derivatives as 5-ht receptor antagonist
ECSP941135A (en) BENZACEPINE VASOPRESSIN TRICYCLIC ANTAGONISTS
PT100514A (en) SUBSTITUTED 3-AMINOKINUCLIDINS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAINS
EA199800868A1 (en) Condensed arylamidopyridines and pyrimidines, containing their pharmaceutical composition, method of treatment, intermediate compounds and method of their production
ES2184797T3 (en) USE OF SEROTONINE ANTAGONISTS (5HT3) FOR THE TREATMENT OF FIBROMIALGIA.
DK0725782T3 (en) A1 adenosine receptor agonists and antiagonists
NO952398D0 (en) Pyrrole pyrimidines as CRF antagonists
ATE254456T1 (en) CANNABINOID RECEPTOR ANTAGONISTS
ES2071486T3 (en) DERIVED FROM 5H-PIRROLO (3,4-B) OPTICALLY ACTIVE PIRAZINE, ITS PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT.
ATE293448T1 (en) BENZO(D)AZEPINE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS
DE69413535D1 (en) 1-PHENYLAL CANNON AS 5-HT4 RECEPTOR LIGANDE
MX9300779A (en) 3- (1H-TETRAZOLE-5-Y1) -4H-PYRIDO [1,2-A] PIRIMIDINA-4-ONAS PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR PREPARATION THEREOF
MX9300948A (en) A NOVEL ANTAGONIST OF THE 5HT3 RECEIVER
ES556864A0 (en) PROCEDURE FOR OBTAINING SUBSTITUTED BENZOPYRANS.
PT684816E (en) ANTAGONIST COMPOSITIONS OF 5-HT2 UTEIS RECEPTOR IN THE TREATMENT OF VENOUS DISEASES
AU3422800A (en) Use of 5-ht3 receptor antagonists
EA199800701A1 (en) BENZO [S] QUINOLYSINUM DERIVATIVES, THEIR RECEIVING AND USE AS INHIBITORS 5a-REDUCTAZ
ES2121984T3 (en) USE OF 5-HT4 ANTAGONISTS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF URINARY INCONTINENCE.
ES2166462T3 (en) ANTIGONISTS OF ENDOTHELINE RECEIVER.
MX9302985A (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF ANXIETY.